CLAIMS:

1. A composition comprising a LTB_4 antagonist having a hydroxy and a benzamidine group, or a tautomer, a pharmaceutically acceptable salt or solvate thereof **(1)**, and a cyclooxygenase-2 inhibitor or combined cox1/coxII inhibitor or a pharmaceutically acceptable salt or solvate thereof **(2)**, and a pharmaceutically acceptable carrier or excipient.

2. The composition according to claim 1 wherein said LTB_4 antagonist is a compound of formula (I)



(I)

wherein

R represents a hydrogen atom or a group of formula $-CO_2-R'$, in which R' represents a C_{1-6} alkyl, an optionally substituted phenyl or an optionally substituted benzyl group, wherein the optional substituents are selected from halogen atoms C_{1-6} alkyl, C_{1-6} alkoxy, cyano, nitro; C_{1-6} haloalkyl and C_{1-6} haloalkoxy groups, and

A is a group selected from the formulae (A1) and (A2):



(A1)



(A2)

or a tautomer, a pharmaceutically acceptable salt or solvate thereof **(1)**.

3. The composition according to claim 2 consisting essentially of the compound of formula (IA)


(IA

(1) and a cyclooxygenase-2 inhibitor or combined cox1/coxII inhibitor selected from the group consisting of celecoxib, Dupont Dup 697, etodolac, etoricoxib, flosulide, meloxicam, nimesulide, parecoxib, rofecoxib, Taisho NS-398 and valdecoxib or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or excipient.

4. The composition according to claim 3 comprising the compound of formula (IA) (1) and meloxicam of formula



or a pharmaceutically acceptable salt thereof (2), and a pharmaceutically acceptable carrier or excipient.

5. The composition according to claim 1 which is in a form suitable for oral, intravascular, intraperitoneal, subcutaneous, intramuscular or topical administration.

6. The composition according to claim 1 wherein the weight ratio of (1) to (2) ranges from 50:1 to 1:300.

7. The composition according to claim 1 wherein a single application dose contains 1 to 10,000 milligrams of the combined active ingredients (1) and (2).

8. The composition according to claim 1 wherein the pharmaceutically acceptable carrier or excipient comprises a carbohydrate.

9. A method for the prevention or treatment of a disease or disorder selected from the group consisting of arthritis, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, asthma, hay fever, atopic dermatitis, rhinitis, bronchitis, COPD, cystic fibrosis, psoriasis, sclerodermia, morbus bechterew, sarcoidosis, tumor metastasis,morbus crohn, colitis ulcerosa, IBD, multiple sclerosis, arteriosclerosis, arteritis, myocardial infarction, stroke, coronary heart disease comprising the administration of an effective amount of a composition comprising a LTB_4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof (**1**) and a cyclooxygenase-2 or combined cox1/coxII inhibitor (**2**), to a patient in a combined form, or separately or sequentially.

10. The method according to claim 9 wherein the composition is administered to a patient for the prevention or treatment of rheumatoid arthritis, atopic dermatitis or coronary heart disease.

11. A method for the manufacture of a medicamentation for the prevention or treatment of disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, asthma, bronchitis, COPD and cystic fibrosis comprising mixing a LTB_4 antagonist having a hydroxy and a benzamidine group, or a tautomer, a pharmaceutically acceptable salt or solvate thereof (**1**) and a cyclooxygenase-2 inhibitor or combined cox1/2 inhibitor (**2**) in a combined form.

12. The method according to claim 11 wherein the medicamentation is effective for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.

13. A pharmaceutical kit comprising at least two separate unit dosage forms (A) and (B) in which:

(A) comprises a composition containing LTB_4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof (**1**), and optionally a pharmaceutically acceptable carrier; and

(B) comprises a composition containing a cyclooxygenase-2 inhibitor or combined cox1/2 inhibitor, and optionally a pharmaceutically acceptable carrier or excipient.